Navigation Links
Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
Date:6/11/2008

AURORA, ON, June 11 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX, FSE: "HBP"), a biopharmaceutical company specializing in the field of cancer therapy, today announced its product development progress, quarterly highlights and financial results for the three and nine month periods ended April 30, 2008.

"During the quarter, we made significant advancements in the development of our lead clinical compounds," said John Docherty, President of Helix Biopharma. "We are currently developing plans for Topical Interferon to enter expanded Phase II/III clinical trials and we are anticipating L-DOS47 entering the clinic in a Phase I study."

HIGHLIGHTS

The Company's highlights for the quarter included the following events:

Clinical Development

- Helix met with the German Federal Institute for Drugs and Medical

Devices (BfArM) as a preliminiary step toward filing its CTA for a

planned large, randomized, placebo-controlled, double-blind Phase III

European clinical trial of Topical Interferon Alpha-2b in patients

with low-grade cervical lesions ("LSIL");

- Helix received approval from the Swedish Medical Products Agency for

a clinical protocol amendment to expand its Topical Interferon

Alpha-2b AGW clinical trial to sites in Germany;

- The Prominent German dermatologist, Professor Dr. med. Eggert

Stockfleth of the Department of Dermatology, Skin Cancer Center

Charite, Universitatsmedizin Berlin, was engaged by Helix to act as

the German co-ordinating investigator for the expanded AGW clinical

trial in Germany;

GMP Manufacturing

- Contract Pharmaceuticals Limited Niagara was engaged by Helix to

further scale-up the Topical Interferon Alpha-2b GMP production

process in anticipation of conducting clinical trials in the U.S. and

Europe in patients with LSIL;

-
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
2. Helix BioPharma reports Q2 2008 highlights, financial results
3. Helix BioPharma shareholders vote in favour of management
4. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
5. Helix BioPharma closes $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma announces $16.9 million private placement of common shares
8. Helix BioPharma Corp. announces management changes
9. Helix BioPharma Corp. announces fiscal 2007 results
10. Helix BioPharma Chairman resigns
11. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 zFlo Motion , a US ... an exciting product from a new partner. STT-Systems ... the past 15 years, with offerings in the optical-motion capture, ... IMU system (inertial measurement unit), iSen, is opening eyes around ...
(Date:1/22/2015)... Diagenode, Inc., a leading global ... and complete solutions for epigenetics research, recently launched ... the need for manual processing. The new ChIPettor ... of histones or transcription factors and a semi-automated ...
(Date:1/22/2015)... GenoSpace , a precision medicine software company that has developed ... of genomic, imaging and other biomedical data in research and ... , CEO of Aspera, an IBM Company, to its board ... "We are pleased to welcome Michelle ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: ... areas, announced the closing of an underwritten public offering of ... to an aggregate 3,500,000 shares of common stock, at an ... The warrants have a per share exercise price of $5.00, ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... FRANCISCO, Calif., May 5 Rigel Pharmaceuticals, Inc. (Nasdaq: ... quarter ended March 31, 2009.For the first quarter of 2009, ... per share, compared to a net loss of $27.3 million, ... Weighted average shares outstanding for the first quarters of 2009 ...
... Uveitis, or inflammation within the eye, is a ... loss roughly comparable to that caused by diabetes. ... program in uveitis, the LUMINATE trials sponsored by ... voclosporin oral capsule) to significantly improve this chronic ...
... The Arcas Group, a leading life-sciences marketing ... as Executive Vice President. He will assume responsibility for ... as President of Imedex, Inc."Stefan is an experienced executive ... our company," said Founder and President Jan Heybroek. ...
Cached Biology Technology:Rigel Announces First Quarter 2009 Financial Results 2Rigel Announces First Quarter 2009 Financial Results 3Rigel Announces First Quarter 2009 Financial Results 4Rigel Announces First Quarter 2009 Financial Results 5First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 2First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 3First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 4The Arcas Group Appoints Executive Vice President 2
(Date:1/22/2015)... Jan. 16, 2015  A man-made form of insulin delivered ... mental capabilities in adults with mild cognitive impairment and ... by researchers at Wake Forest Baptist Medical Center. ... amnesic mild cognitive impairment (MCI) or mild to moderate ...
(Date:1/22/2015)... NEW YORK and POINT ROBERTS, Washington ... global news source covering leading sectors including technology and tech ... Personal Privacy marketplace featuring master pickpocket and security consultant ... wallet is stolen and talks about the Wocket™ biometric smart ...
(Date:1/22/2015)... , Europe,s most ... Patent Office to present a video retrospective of the most exciting ... Christofer Toumazou and Sophie Wilson   ... the Award   Starting on 22 January 2015 on   ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... corn, 1 + 1 = more than 2: The offspring ... of their parents. Characterizing the gene-level variability that leads to ... our ability to custom-tailor crops for specific traits, such as ... for biomass fuel. With help from the newly ...
... A team of researchers at Louisiana Tech University ... a natural herbicide against giant salvinia. Giant salvinia ... block all sunlight penetration into bodies of water, altering ... that giant salvinia can double in size every three ...
... - A new study of maize has identified thousands of ... techniques may allow breeders and researchers to use this genetic ... were not easily possible before. Publishing in the Nov. ... and first author are at Cornell, have identified the first ...
Cached Biology News:U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2Microorganism may provide key to combating giant salvinia throughout Louisiana 2New map of variation in maize genetics holds promise for developing new varieties 2
... Lipid adsorption and clarification reagent; Ideal ... purification of antibodies, proteins, nucleic acids, ... negligible cross-reactivity, and improves downstream processing; ... solid-phase, non-ionic adsorbent supplied as a ...
... is designed to stabilize the biomolecules ... storage. There are neither animal ... is a convenient 10 times solution ... superior to other traditional lyophilizing additives ...
... is the only Gradient thermal cycler which enables ... of a screen. ,Wide linear gradient - ... with an amazing range of,30C. Protocols can be ... - The Touchgene Gradient incorporates a large, 115 ...
... is Tecans open platform for clinical diagnostic ... and performance in the clinical diagnostic and ... flexible barcode reading and sample traceability as ... system complies with the IVD-Directive* established in ...
Biology Products: